About Nifedipine Extended Release Tablet
Nifedipine Extended Release Tablet is a calcium channel blocker and is used to treat Angina and Hypertension. Nifedipine Extended Release Tablet is marketed by J.B. Chemicals & Pharmaceuticals Ltd. and comes in two doses namely Nifedipine Extended Release Tablet 30 mg and Nifedipine Extended Release Tablet 30/60 mg
Nifedipine dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm, and is responsible for the effectiveness of nifedipine in vasospastic (Prinzmetal’s or variant) angina. The mechanism by which nifedipine reduces arterial blood pressure involves peripheral arterial vasodilatation and the resulting reduction in peripheral vascular resistance.
Indications of Nifedipine Extended Release Tablet 30/60
• Hypertension- Nifedipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended Release Tablets. Nifedipine Extended Release Tablet may be used alone or in combination with other antihypertensive agents
• Vasospastic Angina- Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation 2) angina or coronary artery spasm provoked by ergonovine or 3) angiographically demonstrated coronary artery spasm. Nifedipine extended-release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g. where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers.
• Chronic Stable Angina (Classical Effort-Associated Angina)- Nifedipine is indicated for the management of chronic stable angina (effort- associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) Nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete.
Nifedipine Extended Release Tablet Dose and Method of Administration
Nifedipine Dosage must be adjusted according to each patient’s needs. Therapy for either hypertension or angina should be initiated with 30 or 60 mg once daily. Nifedipine Extended Release Tablets should be swallowed whole and should not be bitten or divided. In general, titration should proceed over a 7–14 day period so that the physician can fully assess the response to each dose level and monitor blood pressure before proceeding to higher doses. Since steady-state plasma levels are achieved on the second day of dosing, titration may proceed more rapidly, if symptoms so warrant, provided the patient is assessed frequently. Titration to doses above 120 mg are not recommended. Angina patients controlled on Nifedipine alone or in combination with other antianginal medications may be safely switched to Nifedipine Extended Release Tablets at the nearest equivalent total daily dose (e.g., 30 mg t.i.d. of Nifedipine may be changed to 90 mg once daily of Nifedipine Extended Release Tablets). If discontinuation of nifedipine is necessary, sound clinical practice suggests that the dosage should be decreased gradually with close physician supervision. Care should be taken when dispensing Nifedipine Extended Release Tablets to assure that the extended release dosage form has been prescribed
- Known hypersensitivity reaction to nifedipine. (Download product Leaflet, for details)
Nifedipine Extended Release Tablet should be not used/carefully used following cases
• Excessive Hypotension
• Beta Blocker Withdrawal
• Congestive Heart Failure .
• Gastrointestinal Obstruction Requiring Surgery
• Gastrointestinal Ulcers
• Peripheral Edema:
Download the Product Leaflet, to see the detailed warnings and precautions
Information for Patients: Nifedipine Extended Release Tablets should be swallowed whole. Do not chew, divide or crush tablets. Do not be concerned if you occasionally notice in your stool something that looks like a tablet. In Nifedipine Extended Release Tablets, the medication is contained within a non-absorbable shell that has been specially designed to slowly release the drug for your body to absorb. When this process is completed, the empty tablet is eliminated from your body.
Download the Product Leaflet, to see the detailed drug interactions
Nifedipine Side effects/ Overdose
Download the Product Leaflet, , to see the details on Pharmacodynamic and Pharmacokinetic Properties of Nifedipine Extended Release Tablet XL 30/60 mg
Nifedipine Extended Release Tablet Journal update
• Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
• Resistant Hypertension: Detection, Evaluation, and Management A Scientific Statement From the American Heart Association
• A randomized controlled trial on the blood pressure–lowering effect of amlodipine and nifedipine‐GITS in sustained hypertension
• A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS)
• Long-acting nifedipine for hypertensive patients in the Middle East and Morocco: observations on efficacy and tolerability of monotherapy or combination therapy
• Early intervention of long-acting nifedipine GITS reduces brachial–ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study
• Effectiveness of combination therapy with nifedipine GITS: a prospective, 12-week observational study (AdADOSE)